Eyenovia Announces Corporate Strategy Update Presentation
PremiumCompany AnnouncementsEyenovia Announces Corporate Strategy Update Presentation
2M ago
Eyenovia reports Q1 EPS (23c), consensus (17c)
PremiumThe Fly
Eyenovia reports Q1 EPS (23c), consensus (17c)
2M ago
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
PremiumPress Releases
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
2M ago
Eyenovia considers strategic alternatives, including possible sale
PremiumThe FlyEyenovia considers strategic alternatives, including possible sale
4M ago
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
PremiumPress Releases
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
4M ago
Eyenovia to feature commercial products, Optejet Dispenser at eyecare meetings
PremiumThe Fly
Eyenovia to feature commercial products, Optejet Dispenser at eyecare meetings
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100